Vor Biopharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018
Selling, General & Admin	31.72	28.87	21.49	11.75	4.22	0.43
Research & Development	94.32	64.55	47.53	31.62	6.2	2.43
Operating Expenses	126.04	93.42	69.02	43.37	10.42	2.86
Operating Income	-126.04	-93.42	-69.02	-43.37	-10.42	-2.86
Interest Expense / Income	0	0	0	0	0.61	1
Other Expense / Income	-8.17	-1.32	-0.12	-0.03	-0.19	0.29
Pretax Income	-117.86	-92.09	-68.9	-43.34	-10.84	-4.15
Net Income	-117.86	-92.09	-68.9	-43.34	-10.84	-4.15
Preferred Dividends	0	0	1.23	5.93	1.77	0
Net Income Common	-117.86	-92.09	-70.13	-49.26	-12.61	-4.15
Shares Outstanding (Basic)	67	40	33	0	2	1
Shares Outstanding (Diluted)	67	40	33	0	2	1
Shares Change	69.89%	18.30%	15548.00%	-86.33%	30.97%	-
EPS (Basic)	-1.75	-2.33	-2.10	-230.57	-8.07	-3.48
EPS (Diluted)	-1.75	-2.33	-2.10	-230.57	-8.07	-3.48
Free Cash Flow	-101.36	-93.61	-73.04	-40.45	-10.6	-2.66
Free Cash Flow Per Share	-1.51	-2.37	-2.19	-189.34	-6.78	-2.23
EBITDA	-109.64	-85.99	-64.45	-41.95	-10.14	-3.13
Depreciation & Amortization	8.22	6.1	4.45	1.39	0.09	0.02
EBIT	-117.86	-92.09	-68.9	-43.34	-10.23	-3.15

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).